Found: 4
Select item for more details and to access through your institution.
RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1426446
- By:
- Publication type:
- Article
Inside Cover: Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases (ChemMedChem 2/2016).
- Published in:
- ChemMedChem, 2016, v. 11, n. 2, p. 147, doi. 10.1002/cmdc.201500604
- By:
- Publication type:
- Article
Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases.
- Published in:
- ChemMedChem, 2016, v. 11, n. 2, p. 179, doi. 10.1002/cmdc.201500218
- By:
- Publication type:
- Article
NF‐κB activation in astrocytes drives a stage‐specific beneficial neuroimmunological response in ALS.
- Published in:
- EMBO Journal, 2018, v. 37, n. 16, p. 1, doi. 10.15252/embj.201798697
- By:
- Publication type:
- Article